AURA BIOSCIENCES INC (AURA)
Health Care · biotechnology · NASDAQ
Aura Biosciences is a clinical-stage biotech developing targeted, light-activated virus-like drug conjugates (VDCs) designed to treat ocular cancers while preserving organ function and vision.
What AURA BIOSCIENCES INC does
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for ocular cancers, with a primary emphasis on vision-sparing treatments. Its lead product candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate (VDC) currently in late-stage clinical development for early choroidal melanoma and other ocular oncology indications. The company utilizes a proprietary VDC platform designed to deliver targeted, light-activated cytotoxic payloads to solid tumors while preserving surrounding healthy tissue.
Recent developments
In August 2026, the company announced a strategic pivot to focus resources exclusively on ocular oncology, deprioritizing its bladder cancer (NMIBC) program. This restructuring included a 20% workforce reduction to extend its cash runway into the first half of 2029. The Phase 3 CoMpass trial for bel-sar in early choroidal melanoma has completed enrollment of 108 patients, with topline data expected in 2H 2027.
From AURA BIOSCIENCES INC's filing of 2026-08-11.
Themes: ocular oncology, precision medicine, vision preservation, targeted therapy, clinical-stage biotech
Fundamentals
- Price$6.51 as of 2026-10-08 close
- Market cap$675M as of 2026-08-06 (share count; price 2026-10-08)
- 1-year return+6.8% 2025-10-08 close $6.09 → 2026-10-08 close $6.51
- P/En/a negative earnings
- ROE-77.6% FY2025, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Beta0.94 as of 2026-09-03
- Last reported earnings2026-08-11 SEC EDGAR Form 8-K (Item 2.02)
How AURA compares in its sector
- return on equitybottom 25% 510 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How AURA BIOSCIENCES INC looks technically
AURA BIOSCIENCES INC (AURA) is trading 1.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 118 trading days ago — a "golden cross", a bullish long-term signal. A trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive). It made a new 20-day low about 10 trading days ago. It is 31.8% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 1.9% below its 200-day average, the long-term trend line — a long-term downtrend | -1.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.08 | $7.08 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $6.63 | $6.63 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 118 trading days ago — a "golden cross", a bullish long-term signal | 118 sessions |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 25 (a reading of 25+ marks a strong trend) | 24.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 48, neither overbought (above 70) nor oversold (below 30) | 48.1 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($5.95 to $6.61) — its "stochastic" reading is 84 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 84.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 3 trading days ago (its momentum flipped positive) | 3 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $9.54 | $9.54 |
|---|---|---|
| From the 52-week high | it is 31.8% below its 52-week high (its highest price of the past year) | -31.8% |
| Above the 52-week low | it is 37.5% above its 52-week low (its lowest price of the past year) | +37.5% |
| Below the 52-week high | it is 31.8% below its highest point of the past year | 31.8% |
| Since a 20-day breakout | it made a new 20-day low about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day low about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $25.94 (set on 2021-11-16) | $25.94 |
| Given back of the 52-week move | over the past year its closes ranged ($4.97 to $8.90), and it has given back a bit over half of its rise from last year’s low — 61% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $6.35 to $6.47. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 60.9% |
| From the all-time high | it is 74.9% below its all-time high | -74.9% |
| Nearest price level | it is trading 1.6% below a resistance level at $6.61 — a price it turned at 7 times since 2025-10-16, most recently on 2026-07-13. Since 2024-10-08 it has 6 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.6% |
| All-time low | its lowest closing price on record is $4.34 (set on 2025-05-15) | $4.34 |
| Above the all-time low | it is 49.7% above its all-time low | +49.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 38th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.307 between its high and its low — about 4.7% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.307 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $5.76 and $7.02 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $5.76 – $6.39 – $7.02 |
| Typical daily range (% of price) | its price moves about 4.7% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.7% |
| Stretch from the 200-day average | it is trading 0.4 daily ranges below its 200-day average price (1.9% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.99× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a bullish engulfing | 1 session ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 1 session ago |
|---|---|---|
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.8% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.8% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-18 has been "filled" 14 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 14 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +5.43% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 12.7 percentage points (the stock lost 11.6% while the market gained 1.0%) | -12.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 14.1 percentage points (the stock lost 10.3% while the market gained 3.8%) | -14.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.1 percentage points (the stock lost 2.6% while the market gained 17.5%) | -20.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 8.2 percentage points (the stock gained 6.8% while the market gained 15.0%) | -8.2% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, lagging the market over 6 months, near the top of its 14-day range (overbought), trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 10% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.9% of the share price. | -10.4% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $7.03 — a volume-weighted average of daily closes over 188 sessions, not a true tick-by-tick VWAP. | -7.5% |
|---|---|---|
| Vs the average paid since it last reported | the price is 7% below the average price paid since it last reported on 2026-08-11 (its 10-Q), so the typical buyer over that stretch is under water. That average is $6.97 — a volume-weighted average of daily closes over 42 sessions, not a true tick-by-tick VWAP. | -6.7% |
Price levels it has turned at before
AURA last closed at $6.50 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 10 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $6.61 | Resistance | 1.6% above the last close | turned there 7 times · 2025-10-16 to 2026-07-13 |
| $6.33 | Support | 2.7% below the last close | turned there five times · 2025-05-02 to 2026-03-03 |
| $6.76 | Resistance | 3.9% above the last close | turned there four times · 2025-08-26 to 2026-08-03 |
| $6.11 | Support | 6.0% below the last close | turned there four times · 2025-08-20 to 2026-06-11 |
| $7.08 | Resistance | 8.9% above the last close | turned there four times · 2025-03-11 to 2026-05-19 |
| $5.90 | Support | 9.4% below the last close | turned there 8 times · 2025-04-23 to 2026-09-24 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · lagging the market · At the top of its 14-day range (stochastic above 80) · Near the golden pocket (has given back about two thirds of its 52-week move) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$16.60 range $12.00 – $23.00; median $15.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Heavy dependence on the clinical success and regulatory approval of a single lead candidate, bel-sar.","History of operating losses and no commercial revenue, with a significant reliance on raising capital for ongoing operations.","Clinical trial execution risks, including reliance on third-party contract research and manufacturing organizations."]
What changed in the latest 10-Q
AI-assisted comparison of AURA's 10-Q filed 2026-08-11 against the prior one filed 2026-05-11.
Management's Discussion & Analysis (MD&A)
- Added:
- In the newer filing (2026-08-11), a new subsection 'NMIBC Program Update' was added describing interim Phase 1b/2 data in NMIBC announced in August 2026, including response rates, durability, and safety profile, as well as a statement that the company is minimizing resource allocation toward the NMIBC program and intends to complete 12-month follow-up data collection.
- In the newer filing (2026-08-11), a new subsection 'Organizational and Leadership Updates' was added stating that in August 2026 the Board of Directors approved a plan to streamline operations with a reduction in force of approximately 20% of the workforce, and that Susan Abu-Absi was appointed Chief Operating Officer, Erica Kratz as Chief Regulatory and Quality Officer, and Julie Person as Chief People Officer.
- In the newer filing (2026-08-11), the phrase 'promising clinical benefit' replaces 'clinical benefit' in the description of bel-sar's performance in clinical trials.
- In the newer filing (2026-08-11), the sentence about bel-sar having potential to change the treatment paradigm was changed from 'patients with ocular and urologic cancers and other solid tumors' to 'patients with ocular cancers and other solid tumors'.
- In the newer filing (2026-08-11), the description of the safety profile was changed from 'highly favorable' to 'favorable'.
- In the newer filing (2026-08-11), a new subsection 'Financing History' was added, though the text is truncated and cannot be fully analyzed.
- Removed:
- In the older filing (2026-05-11), the description of bel-sar's clinical development included 'and bladder cancer' after 'other ocular oncology indications', which was removed in the newer filing.
- In the older filing (2026-05-11), the overview stated that bel-sar is in clinical development for 'metastases to the choroid and bladder cancer', which was changed in the newer filing to only 'metastases to the choroid'.
- In the older filing (2026-05-11), a paragraph beginning 'Beyond ocular cancers, bel-sar is in clinical development in bladder cancer...' describing bladder cancer epidemiology and the Phase 1 NMIBC trial (NCT05483868) and ongoing Phase 1b/2 trial was removed in the newer filing.
- In the older filing (2026-05-11), a paragraph about incorporation in Delaware in 2009 and financing history through May 5, 2026 was removed in the newer filing.
- Reworded:
- The sentence 'We believe bel-sar, if approved, has the potential to change the current treatment paradigm for patients with ocular and urologic cancers and other solid tumors' in the older filing (2026-05-11) was changed to 'We believe bel-sar, if approved, has the potential to change the current treatment paradigm for patients with ocular cancers and other solid tumors' in the newer filing (2026-08-11).
- The phrase 'The safety profile of bel-sar was highly favorable in all participants regardless of dose' in the older filing (2026-05-11) was changed to 'The safety profile of bel-sar was favorable in all participants regardless of dose' in the newer filing (2026-08-11).
- The phrase 'Bel-sar has shown clinical benefit and has been generally well-tolerated in clinical trials to date' in the older filing (2026-05-11) was changed to 'Bel-sar has shown promising clinical benefit and has been generally well-tolerated in clinical trials to date' in the newer filing (2026-08-11).
- In the older filing (2026-05-11), the sentence beginning 'Moreover, we intend to assess the safety and efficacy of bel-sar...' referred to 'metastases to the choroid and bladder cancer where bel-sar is in clinical development' while the newer filing (2026-08-11) refers only to 'metastases to the choroid where bel-sar is in clinical development'.
- The older filing (2026-05-11) included a section on bladder cancer development not present in the newer filing (2026-08-11).
- Notes:
- The newer filing text is truncated at 'Financing History' and the older filing text is truncated mid-sentence, so content after those points could not be compared.
- No assessment of materiality or significance of changes is made per instructions.
Risk Factors
- Reworded:
- The newer filing (2026-08-11) states: 'We have completed enrollment in our pivotal Phase 3 clinical trial, but we do not expect topline data until the second half of 2027, and we have not yet completed such trial nor commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects.' The older filing (2026-05-11) states: 'We have initiated but not yet completed a pivotal clinical trial nor have we commercialized any pharmaceutical products, which may make it difficult to evaluate our future prospects.'
- Notes:
- The newer filing text ends mid-sentence with 'international tariffs' in the forward-looking statements section; the older filing continues with 'trade protection measures, economic sanctions and economic slowdowns or recessions, on our business'. The provided excerpt of the newer text may be truncated, so a complete comparison of the forward-looking statements section could not be performed.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 3 sells ($39M) — 3 selling insiders
Most recent open-market transaction: 2026-06-16. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about AURA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding AURA as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 6,463,993
- Reported value $45,894,351
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about AURA's institutional holders → See what each manager we track holds →
Short interest (FINRA)
AURA had 7,049,973 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
AURA had 6.80% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 11.66 days to cover at the same settlement.
- Reported short interest (shares) 7,049,973
- Short interest (% of shares outstanding) 6.80%
- Prior settlement (shares) 6,203,498
- Reported change 13.65%
- Days to cover (reported) 11.66
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Castle Biosciences (CSTL)
- Immunocore (IMCR)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare AURA vs…
AURA BIOSCIENCES INC is found in…
Frequently asked questions
What does AURA BIOSCIENCES INC (AURA) do?
Aura Biosciences is a clinical-stage biotechnology company focused on developing precision therapies for ocular cancers, with a primary emphasis on vision-sparing treatments. Its lead product candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate (VDC) currently in late-stage clinical development for early choroidal melanoma and other ocular oncology indications.
What sector is AURA BIOSCIENCES INC (AURA) in?
AURA BIOSCIENCES INC (AURA) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are AURA BIOSCIENCES INC's (AURA) competitors?
Notable peers of AURA BIOSCIENCES INC (AURA) include Castle Biosciences and Immunocore. This peer set is informational only — not financial advice.
Is AURA BIOSCIENCES INC (AURA) overbought or oversold right now?
AURA BIOSCIENCES INC (AURA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 48, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on AURA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.